Amneal Pharmaceuticals has received FDA approval for its pyridostigmine bromide ER tablets, 105 mg, a once-daily oral medication designed for pretreatment against the lethal effects of soman nerve agent poisoning in adults. Developed for the U.S. armed services and its allies, this approval marks a significant advancement in protecting military personnel from chemical warfare threats.
This new formulation offers a substantial improvement over the existing pyridostigmine bromide product, which requires administration every eight hours. The extended-release tablet aims to enhance compliance by providing a steady, 24-hour release of the drug, eliminating the need for service members to self-administer the medication three times a day.
Grande Technology for Sustained Release
The pyridostigmine bromide ER tablets utilize Amneal’s Grande drug delivery technology, an advanced gastric retention system that ensures sustained drug release. This technology is crucial for maintaining therapeutic drug levels over a 24-hour period, providing consistent protection against nerve agent exposure. The development of this product was partially funded by the U.S. government under Agreement W911QY-21-9-0018.
Executive Perspective
"Amneal is proud to receive our second NDA approval this year, after the recent approval of CREXONT for Parkinson’s disease," said Chirag and Chintu Patel, co-CEOs of Amneal. "This new pyridostigmine therapy speaks to Amneal’s expertise in developing new innovative product formulations and our ongoing work with the U.S. government on new solutions. With the approval of pyridostigmine bromide extended-release tablets, we are proudly supporting the U.S. military."
